A Phase 3, Controlled, Open-label, Global Randomized Study of RRx-001 With a Platinum Doublet or a Platinum Doublet in Small Cell Lung Cancer

NCT05566041 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

292

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Small Cell Lung

Interventions

DRUG: RRx-001 + eLOOP Device
DRUG: Cisplatin/carboplatin plus etoposide

Sponsor

EpicentRx, Inc.

Collaborators

[object Object]